Glaukos Corporation (GKOS) shares have gained 36.8% over six months, outperforming its industry, driven by strong Q2 results with 50% revenue growth to $185.6 million, successful commercial expansion of Epioxa for keratoconus treatment, positive clinical data for iDose TR, and pipeline advances including a new retinal disease licensing agreement. The company raised its 2026 revenue guidance to $680-$700 million.

Glaukos Corporation announced a licensing agreement with RevOpsis Therapeutics to develop RO-104, a first-in-class tri-specific biologic for retinal diseases, and gained exclusive access to the RevMod platform for up to four additional retinal biologic candidates. Despite the strategic expansion, GKOS stock declined 6.3% following the announcement, though it has gained 42.8% year-to-date.

Intuitive Surgical's single-port (SP) platform is emerging as a significant growth franchise with 61% year-over-year procedure growth and an installed base of 445 systems. Strong U.S. utilization gains (25% YoY) and expanding stapler adoption (nearly 60% of eligible cases) support the platform's trajectory toward becoming a billion-dollar business. The company is also expanding internationally and through product innovation.

Intuitive Surgical is prioritizing R&D investment over near-term profitability to drive long-term growth, focusing on AI/ML, robotics, and expanding into new clinical areas like GI, cardiac, and lung procedures. The company is sacrificing near-term expense leverage to build competitive moats and broaden its addressable market. Peer companies Edwards Lifesciences and Glaukos are similarly investing heavily in R&D to strengthen their competitive positions.

Glaukos CFO Alex Thurman sold 10,000 shares worth $1.6 million on July 9, 2026, under a pre-established Rule 10b5-1 trading plan adopted in December 2025. While insider sales can raise concerns, the non-discretionary nature of this transaction and Glaukos' strong growth outlook—including 25% projected revenue growth for 2026 and the promising Epioxa product—suggest the sale does not indicate trouble for the company.

Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott trades at a lower valuation multiple but faces integration challenges and legal risks, while Glaukos shows rapid 32% revenue growth but remains unprofitable and dependent on a single manufacturing location.

The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.

Nicox plans to fully repay its financial debts by 2026 after successfully licensing NCX 470 globally with Kowa and Ocumension Therapeutics, with New Drug Application submissions expected in the first half of 2026 in the US and later in China.

Nicox anticipates fully repaying its financial debts in 2026 following successful NCX 470 clinical trials and global licensing deals with Kowa and Ocumension Therapeutics, with expected NDA submissions in the U.S. and China in H1 2026.

Glaukos Corporation is focused on developing and commercializing surgical devices and pharmaceutical therapies for glaucoma treatment. The company's iStent product line and global glaucoma and Corneal Health franchises are performing well, despite competition and supply chain challenges. Glaukos is also advancing its pipeline, including iDose TREX, iDose ROCK, and iLution Travoprost.

Boston Scientific Corporation is scheduled to report its Q2 2024 results on July 24. The company is expected to report revenue growth of around 11.7% and adjusted earnings of 58 cents per share. However, the company may face challenges from a challenging supply environment, rising costs, and healthcare staffing shortages.

Truist Securities has raised its price target for Glaukos Corporation shares to $141, citing the company's strong market position and the potential of its iDose product. The firm maintains a Buy rating on the stock.